Hepatitis C direct-acting antiviral outcomes in patients 75 years and older.
Parmvir ParmarStephen D ShafranSergio M BorgiaKaren DoucetteCurtis L CooperPublished in: JGH open : an open access journal of gastroenterology and hepatology (2020)
Ribavirin-free DAA therapy is safe and achieves SVR rates in older adults comparable to those described in the general population. RBV inclusion frequently results in complications, often leads to treatment modification or interruption, and does not improve SVR rates in those with advanced age.